Director/PDMR Share Dealings
Director/PDMR Share Dealings
Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) of the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from October 1 to December 31, 2014.
| Type of Security (1) | Number of Shares/ADSs | |
| Dominic Blakemore | Shares | 122 |
| William Burns | Shares | 119 |
| Dr. Steven Gillis | ADSs | 37 |
| Dr. David Ginsburg | ADSs | 41 |
| David Kappler | Shares | 123 |
| Susan Kilsby (2) | ADSs | 150 |
| Anne Minto | Shares | 119 |
| David Stout | ADSs | 37 |
(1) One ADS is equal to three Shares.
(2) On October 23, 2014, Susan Kilsby’s fee as Chairman of Shire plc was increased to £450,000 per annum effective as of September 1, 2014. Twenty-five per cent of this amount will continue to be paid in stock. The number of ADSs acquired for Ms Kilsby, as referenced above, includes ADSs acquired in respect of the pro rata amount of her fee increase for the month of September, 2014.
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £46.4937 per Share and $217.4953 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
Investor Relations
Jeff Poulton
[email protected]
+1 781 482 0945
Sarah Elton-Farr
[email protected]
+44 1256 894157
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
Click here for the PDF version of this press release.